Which bucket you're in decides everything. The current rules sort adults three ways 1:
- 75 or older: recommended, full stop, however healthy you are. One shot.
- 50 to 74: recommended only if you carry a risk condition.
- No qualifying risk and under 75: not routinely recommended, though some choose it after a doctor conversation.
The risk conditions that move you into the yes column: chronic heart or lung disease (COPD, heart failure, asthma), diabetes with kidney, eye, or nerve damage, serious kidney or liver disease, a BMI of 40 or higher, a weakened immune system, sickle cell disease, frailty, or living in long-term care.
The shot works, and the real-world data backs the trials. Three big trials found it prevented roughly two-thirds to over four-fifths of RSV lower respiratory illness in the first season, with protection against the most severe outcomes running higher still 234. Tracking actual hospitalizations across a full season, vaccinated adults 60 and up were about 75 to 80 percent less likely to land in the hospital for RSV 5. Protection against milder illness fades by year two; protection against severe disease holds up. It's one lifetime dose, no booster.
If you're in a yes bucket, here's the move. Time it so peak protection lands before RSV season, which runs November through March.
You're covered within two to four weeks of the shot.
What it costs you. The typical reaction is a sore arm and maybe a day of feeling tired or achy, like the Shingrix shot. The price tag is usually zero: Medicare Part D and ACA-compliant private plans cover it with no copay. Uninsured cash price runs about $280 to $320.
The fine print — when to skip it, and what people get wrong
Skip it if you've had a severe allergic reaction to a prior RSV shot. Vaccinated adults had about seven to nine extra Guillain-Barré cases per million doses; the CDC kept the recommendation because far more hospitalizations and deaths are prevented 1.
Pregnant: get Abrysvo only, in a set window, to protect the baby; Arexvy and mResvia aren't for you. "I had RSV, so I'm immune" is false; immunity fades and adults catch it repeatedly. Healthy 65-year-olds aren't on the routine list; the floor moved to 75.
- 1Britton A, Roper LE, Kotton CN, et al. (2024). Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morbidity and Mortality Weekly Report. link
- 2Papi A, Ison MG, Langley JM, et al. (2023). Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal of Medicine. link
- 3Walsh EE, Pérez Marc G, Zareba AM, et al. (2023). Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. New England Journal of Medicine. link
- 4Wilson E, Goswami J, Baqui AH, et al. (2023). Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. New England Journal of Medicine. link
- 5Surie D, Yuengling KA, DeCuir J, et al. (2024). Early Estimate of Respiratory Syncytial Virus Vaccine Effectiveness Against RSV-Associated Hospitalization Among Adults Aged ≥60 Years — IVY Network, United States. MMWR Morbidity and Mortality Weekly Report. link
დაკავშირებული სახელმძღვანელოში (3)
- — RSV is one of the shots on the adult schedule, with its own age and risk gate before you qualify.
- — COPD is exactly the kind of lung condition that both raises your RSV risk and qualifies you for the vaccine earlier.
- — Not sure if you're old enough or sick enough to need the RSV shot yet? This walks the eligibility line.
RSV Vaccine for Adults
Since the Inflation Reduction Act (Jan 2023), all ACIP-recommended adult vaccines are covered with no cost-sharing under Medicare Part D. ACA-compliant private insurance covers RSV vaccination as a preventive service with no cost-sharing. Cash price approximately $280-320/dose for uninsured patients. For nearly all eligible US adults the realized cost is $0.
Single intramuscular dose, once in a lifetime under current ACIP guidance. ~24-48 h of injection-site pain and mild systemic reactogenicity (fatigue, myalgia) at incidence comparable to Shingrix. No ongoing behavioral effort. Walk-in pharmacy administration available without prescription in most US states.
In eligible older adults, three phase 3 RCTs (Papi 2023 AReSVi-006; Walsh 2023 RENOIR; Wilson 2023 ConquerRSV) showed first-season VE of 67-86% against RSV-LRTD and 86-94% against severe LRTD. Real-world IVY/VISION case-control studies show 75-80% VE against RSV hospitalization in adults ≥60 (Surie 2024). Population burden of 60,000-160,000 US hospitalizations and 6,000-10,000 deaths annually in adults ≥60 (Hansen 2022) translates to a substantial absolute mortality reduction in the target population — one of the more impactful single preventive interventions available to the 75+ cohort, though not catalogue-wide dominant because benefit is concentrated in older / risk-stratified adults.
Three independent large phase 3 RCTs (Papi 2023, Walsh 2023, Wilson 2023) plus replicated real-world VE against hospitalization in CDC IVY and VISION case-control networks (Surie 2024). ACIP- and FDA-backed; international advisory body alignment. Not a 5 because two-season durability data show meaningful waning at the mild-endpoint margin and the GBS postmarketing signal remains under active surveillance.